Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: A retrospective study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Jacot, William ^a   Gerlotto Borne, Marie Cécile ^a   Thezenas, Simon ^a   Pouderoux, Stéphane ^a   Poujol, Sylvain ^a   About, Mahdi ^a   Romieu, Gilles ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; METHOTREXATE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMORBIDITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; BRAIN TUMOR; BREAST TUMOR; FEMALE; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SKULL IRRADIATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77952966235     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-257     Document Type: Article

References (35)

1. Hutter A, Schwetye KE, Bierhals AJ, McKinstry RC. Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am 2003, 13(2):237-250. x-xi, 10.1016/S1052-5149(03)00016-9, 13677804.
2. Kirsch DG, Loeffler JS. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer 2005, 6(2):115-124. 10.3816/CBC.2005.n.013, 16001989.
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004, 22(17):3608-3617. 10.1200/JCO.2004.01.175, 15337811.
4. Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, Wilkinson PM, Welch RS, Magee B, Wilson G, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004, 91(4):639-643. 2364775, 15266327.
5. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979, 44(5):1913-1918. 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D, 498057.
6. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983, 52(12):2349-2354. 10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B, 6640506.
7. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97(12):2972-2977. 10.1002/cncr.11436, 12784331.
8. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist 2003, 8(5):398-410. 10.1634/theoncologist.8-5-398, 14530493.
9. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10(11):1037-1044. 10.1016/S1470-2045(09)70263-3, 19801201.
10. Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie 2002, 25(5):474-479. 10.1159/000067443, 12415203.
11. Rosner D, Nemoto T, Lane WW. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986, 58(4):832-839. 10.1002/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W, 3755076.
12. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 1982, 42(6):2474-2479.
13. Lassman AB, Abrey LE, Shah GD, Panageas KS, Begemann M, Malkin MG, Raizer JJ. Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006, 78(3):255-260. 10.1007/s11060-005-9044-6, 16344918.
14. Cascino TL, Byrne TN, Deck MD, Posner JB. Intra-arterial BCNU in the treatment of metastatic brain tumors. J Neurooncol 1983, 1(3):211-218. 10.1007/BF00165605, 6678970.
15. Zubrod C, Schneiderman M, Frei EJ. Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard an triethylene thiophosphoramide. J Chron Dis 1960, 11:7-33.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216. 10.1093/jnci/92.3.205, 10655437.
17. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958, 53:457-481.
18. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990, 8(12):1935-1937.
19. Chow LW, Yip AY, Lang BH. A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer. Am J Clin Oncol 2007, 30(2):133-138. 10.1097/01.coc.0000251400.47711.fe, 17414461.
20. Eichbaum MH, Gast AS, Schneeweiss A, Bruckner T, Sohn C. Activity and tolerability of a combined palliative chemotherapy with mitomycin C, folinate, and 5-Fluorouracil in patients with advanced breast cancer after intensive pretreatment: a retrospective analysis. Am J Clin Oncol 2007, 30(2):139-145. 10.1097/01.coc.0000251935.51345.10, 17414462.
21. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I. Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004, 43(2):186-189. 10.1080/02841860310023165, 15163168.
22. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007, 85(2):223-227. 10.1007/s11060-007-9409-0, 17611719.
23. Wadasadawala T, Gupta S, Bagul V, Patil N. Brain metastases from breast cancer: management approach. J Cancer Res Ther 2007, 3(3):157-165. 10.4103/0973-1482.37409, 18079579.
24. Ogawa K, Yoshii Y, Nishimaki T, Tamaki N, Miyaguni T, Tsuchida Y, Kamada Y, Toita T, Kakinohana Y, Tamaki W, et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol 2008, 86(2):231-238. 10.1007/s11060-007-9469-1, 17849084.
25. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322(8):494-500.
26. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992, 69(4):972-980. 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO;2-P, 1735089.
27. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37(4):745-751.
28. Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999, 85(7):1599-1605. 10.1002/(SICI)1097-0142(19990401)85:7<1599::AID-CNCR23>3.0.CO;2-#, 10193952.
29. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, Broglio K, Yin G, Hortobagyi GN, Buchholz T. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006, 107(6):1348-1354. 10.1002/cncr.22127, 16909414.
30. Viani GA, Castilho MS, Salvajoli JV, Pellizzon AC, Novaes PE, Guimaraes FS, Conte MA, Fogaroli RC. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems. BMC Cancer 2007, 7:53. 10.1186/1471-2407-7-53, 1851018, 17386108.
31. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008, 112(11):2359-2367. 10.1002/cncr.23468, 18361426.
32. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 2008, 10(1):R20. 10.1186/bcr1870, 2374976, 18307763.
33. Park IH, Ro J, Lee KS, Nam BH, Kwon Y, Shin KH. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer. Ann Oncol 2009, 20(1):56-62. 10.1093/annonc/mdn539, 18664558.
34. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008, 26(12):1993-1999. 10.1200/JCO.2007.12.3588, 18421051.
35. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roche H, Liu MC, Greil R, Ciruelos E, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15(4):1452-1459. 10.1158/1078-0432.CCR-08-1080, 19228746.